ClinicalTrials.gg

Program

GZR4

A development code. Also written as “GZR4 Injection”.

Its studies are mostly in Diabetes Mellitus · Diabetes Mellitus, Type 2, led by Gan & Lee Pharmaceuticals.

Furthest: phase 3, since Jan 5, 20259 company-led studies, 5 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gan & Lee Pharmaceuticals95 open or runningphase 3since Jan 5, 2025Jan 2, 2024none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jan 2, 2024First study: phase 2 study in Diabetes Mellitus, Type 2First studyNCT06202079 · 179 enrolled · China
  2. Aug 5, 20244 phase 1 studiesNCT06548815, NCT06553248, NCT06547502 and 1 more
  3. Jan 5, 20252 phase 3 studies in Diabetes MellitusNCT06767761, NCT06767735
  4. Sep 3, 2025Phase 3 study in Diabetes MellitusNCT07165223 · 300 planned · China
  5. Sep 18, 2025Phase 1 study in Diabetes MellitusNCT07193147 · 36 enrolled · China

Ahead

  1. Nov 10, 2026Primary completion: phase 3 study in Diabetes MellitusNCT07165223

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 9 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07193147Diabetes Mellitus · China1Active, not recruitingJul 14, 202636
NCT07165223Diabetes Mellitus · China3RecruitingNov 10, 2026300
NCT06767761Diabetes Mellitus · China3Active, not recruitingMar 19, 2026580
NCT06767735Diabetes Mellitus · China3Active, not recruitingAug 1, 2026580
NCT06548906Healthy Subjects · China1RecruitingAug 31, 202424
NCT06553248Diabetes Mellitus · China1CompletedNov 1, 202336
NCT06547502Diabetes Mellitus · China1CompletedAug 20, 202416
NCT06548815Diabetes Mellitus · China1CompletedMar 24, 202343
NCT06202079Diabetes Mellitus, Type 2 · China2CompletedJul 13, 2024179

How it is read

Names in the registry

  • “GZR4”, 7 entries
  • “GZR4 Injection”, 2 entries

Codes read as this program: GZR4.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.